Sign In
Buy GLMD
$0.621
+0.0220 (+3.67%)
At Close: Jul 31, 2026
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2021 Results - Earnings Call Transcript
11:00am, Monday, 09'th Aug 2021
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2021 Results - Earnings Call Transcript
GLMD Stock Increases Over 4% Pre-Market: Why It Happened
08:29am, Monday, 02'nd Aug 2021
The stock price of Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) increased by over 4% pre-market. This is why it happened.
TEL AVIV, Israel, Aug. 2, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q1 2021 Results - Earnings Call Transcript
06:58pm, Thursday, 13'th May 2021
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q1 2021 Results - Earnings Call Transcript
Galmed Pharmaceuticals Provides Business Updates and Reports First Quarter 2021 Financial Results
07:50am, Thursday, 13'th May 2021
TEL AVIV, Israel, May 13, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the live
Week In Review: WHO Close To Approving Global Use For 2 China COVID-19 Vaccines
02:00am, Monday, 10'th May 2021
The WHO approved Sinopharm's COVID-19 vaccine for emergency use, which will give poorer nations access to a vaccine against the global pandemic. CoronaVac is the first China-developed COVID-19 vaccine
Galmed Pharmaceuticals to Report First Quarter 2021 Financial Results and Provide Business Update on Thursday May 13
08:30am, Thursday, 06'th May 2021
TEL AVIV, Israel, May 6, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol,
TEL AVIV, Israel, May 3, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory
GLMD Stock Price Increased 14.62%: Why It Happened
12:20am, Monday, 22'nd Mar 2021
The stock price of Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) has increased by 14.62% on March 19. This is why it happened.
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q4 2020 Results - Earnings Call Transcript
10:38am, Thursday, 18'th Mar 2021
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q4 2020 Results - Earnings Call Transcript
Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2020 Financial Results
07:00am, Thursday, 18'th Mar 2021
TEL AVIV, Israel, March 18, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the li
Galmed Pharmaceuticals Announces Dosing of First Subject in First in Human Phase 1 Trial of Amilo-5MER
08:00am, Tuesday, 16'th Mar 2021
TEL AVIV, Israel, March 16, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company today announced the treatment of the
Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2020 Financial Results and Provide Business Update on Thursday March 18
08:30am, Thursday, 11'th Mar 2021
TEL AVIV, Israel, March 11, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramch
Galmed to add Open Label Part to ARMOR Study; First Read-out Expected in Q4 2021
08:09am, Thursday, 17'th Dec 2020
TEL AVIV, Israel, Dec. 17, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory
Week In Review: Baidu Raising $2 Billion For New China Biopharma
11:40am, Sunday, 13'th Sep 2020
Baidu, one of China's major internet/AI companies, is talking with investors about raising $2 billion to fund a new China drug development and diagnostics company.
